Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1
18+
5 sites in FL, TX, VA
What this study is about
This Phase 1 study is focused on people with advanced metastatic cancer. The primary outcome being measured is Assessment of the MTD and/or RP2D (recommended Phase II dose) (Phase 1a).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Assessment of the MTD and/or RP2D (recommended Phase II dose) (Phase 1a)., Incidence of Treatment-Emergent Adverse Events and dose-limiting toxicities (DLTs) [Safety and Tolerability] of SYS6043 during the study (Phase 1a)
Secondary: B7-H3 protein expression levels, Objective response rate (ORR), SYS6043 Pharmacokinetic
Oncology, Reproductive Health